When TV presenter cherry healey was 40 she encountered debilitating anxiety and alarming heart palpitations that nearly led her to start antidepressants before she and clinicians recognised a hormonal cause. Her account includes a startling link between depleting oestrogen and recurrent urinary tract infections that culminated in a life-threatening sepsis scare. Healey has since argued that perimenopause — not menopause — is the pivotal phase for many women, reframing a conversation often limited to hot flushes and irregular periods.
Cherry Healey: Why this matters right now
Cherry Healey’s story matters because it highlights a misdiagnosis crisis affecting women in their forties. In her account she describes symptoms that began at age 40 — sudden, severe anxiety and heart palpitations — which were initially treated as mental health issues. The near-decision to take antidepressants before recognising a hormonal driver underlines how perimenopausal physiology can be missed. Beyond emotional and cardiovascular sensations, Healey experienced recurrent UTIs that she links to falling oestrogen levels, a progression that escalated into a sepsis scare. That trajectory turns what is frequently framed as an emotional or midlife problem into a potentially acute medical emergency, demanding renewed clinical attention to perimenopausal presentations.
Deep analysis: What lies beneath the headline?
From the details presented, two interlocking threads explain the severity of Healey’s experience. First, fluctuating hormones during perimenopause can produce psychological symptoms — in her case debilitating anxiety — and somatic signs such as heart palpitations and disturbed sleep. Second, falling oestrogen appears in her narrative as a biological factor that may weaken urinary tract tissue resilience, increasing susceptibility to infections. In Healey’s account those infections were not minor annoyances: they set the stage for a life-threatening septic event.
These linked pathways shift the frame of perimenopause from a passage marked chiefly by menstrual irregularity and hot flushes to a multifaceted transition with mental-health, cardiovascular and infectious-disease consequences. The practical implications include the risk that women who present with anxiety, palpitations or recurrent UTIs in their forties will be diverted into siloed care pathways — mental health, cardiology, or urology — without a unifying hormonal diagnosis. That fragmentation can delay targeted hormonal assessment or management and, in cases like Healey’s, allow medical risk to escalate.
Expert perspectives and regional / global impact
Cherry Healey has spoken publicly about the misdiagnosis crisis and her belief that perimenopause is the ‘main event’ rather than menopause. Her testimony, delivered on the Well Enough podcast with Emma Barnett, directly links a constellation of symptoms — anxiety, heart palpitations and recurrent UTIs — to the hormonal shifts of perimenopause. Emma Barnett, the podcast host, facilitated that discussion and foregrounded Healey’s description of how close she came to being prescribed antidepressants before the hormonal explanation emerged.
Regionally and more broadly, Healey’s narrative signals consequences for clinical practice and public health messaging. If women in their forties are routinely channelled into single-specialty clinics without consideration of perimenopause, both morbidity and healthcare costs may rise. The sepsis scare in Healey’s account underscores that untreated or recurrent UTIs in the context of falling oestrogen are not purely quality-of-life issues but can evolve into acute, system-wide threats. Health systems and clinicians will need to reconcile fragmented care models with the integrative needs revealed by first-person accounts such as this.
At the same time, uncertainties remain. The account links oestrogen decline to increased UTI vulnerability and to sepsis risk in this individual case; causal pathways and broader population-level patterns are not enumerated here. What stands out, however, is the consistency of symptoms across psychological, cardiovascular and infectious domains in a single perimenopausal timeline.
As the perimenopause conversation evolves, cherry healey’s experience asks clinicians, policymakers and the public to reassess which phase of reproductive ageing demands priority attention and resources. Will the medical community treat perimenopause as the ‘main event’ and adjust diagnostic pathways accordingly, or will these warning stories be treated as exceptions rather than signals?
